| Summary: | Introduction: Triple-Negative Breast Cancer (TNBC) constitutes patients with estrogen and progesterone hormone receptors negativity, Her 2-neu negativity and variable expressions of Ki67 (proliferative marker), EGFR and CK 5/6 cytokeratins. Standard treatment protocols have failed to improve the overall prognosis and DFS in TNBC, unlike other subtypes. Objective: Our retrospective study aims to identify the TNBC patients treated at rural tertiary medical college and determine their pattern of care and survival. Methods: A single institutional retrospective study was conducted on patients with TNBC subtype, registered at tertiary rural medical college, between May 2012 and April 2017. The study population included female patients, aged 15-70 years, with histology proven carcinoma of the breast, AJCC TNM 7th edition staging I to IV, hormone (ER and PR) and HER-2neu receptors negative, who had undergone surgery, chemotherapy and radiation (curative or palliative), either in neoadjuvant or adjuvant or palliative settings. Disease-Free Survival (DFS) and Overall Survival (OS) curves were calculated using the Kaplan-Meier method. Results: A total of 284 patients were eligible for study analysis. The median age was 45 years. 63.4% of patients presented with T3 or T4 tumour. Similarly, 165 (58.1%) patients presented with nodal disease. AJCC TNM stage II and III combined accounted for 90.1% of patients. 14 individuals had metastases at the time of diagnosis with lung, liver and bones being affected. The 5 years DFS in months was 63.3% with events occurring in 100 individuals. Conclusion: TNBC is an aggressive luminal breast carcinoma with advanced disease presentation, poor outcome to standard conventional chemotherapy and radiation resulting in reduced DFS and OS. © IJCRR.
|
|---|
